Atea Pharmaceuticals (AVIR) Other Working Capital Changes (2021 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly Other Working Capital Changes came in at -$53000.0 in Q1 2026, down 12.77% year-on-year from -$60756.1 in Q1 2025, and down 12.77% quarter-over-quarter from -$47000.0 in Q4 2025.
Atea Pharmaceuticals (AVIR) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Atea Pharmaceuticals' Other Working Capital Changes history runs 6 years deep, the most recent figure standing at -$53000.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes fell 12.77% year-over-year to -$53000.0 in Q1 2026; TTM through Mar 2026 was -$196000.0, a 10.11% decrease from a year earlier, with the FY2025 full-year figure at -$190000.0, down 8.57% from the prior year.
- Other Working Capital Changes slipped to -$53000.0 in Q1 2026 per AVIR's latest filing, from -$47000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $8.5 million in Q3 2024 and bottomed at -$6.2 million in Q4 2024.
- The 5-year median for Other Working Capital Changes is -$88000.0 (2026), against an average of $181764.7.
- Across the five-year window, Other Working Capital Changes soared 99.98% in 2022 and declined 17.14% in 2023, its largest moves.
- Year by year, Other Working Capital Changes stood at -$35000.0 in 2022, then declined by 17.14% to -$41000.0 in 2023, then retreated by 9.76% to -$45000.0 in 2024, then decreased by 4.44% to -$47000.0 in 2025, then declined by 12.77% to -$53000.0 in 2026.
- Per Business Quant, the three latest AVIR Other Working Capital Changes figures stand at -$53000.0 (Q1 2026), -$47000.0 (Q4 2025), and -$48000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Jun 30, 2025 | -48,000.00 |
| Jun 30, 2025 | -48,000.00 |
| Jun 30, 2025 | -48,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Sep 30, 2024 | -43,000.00 |